Clinical Trial Search

Primary: Mean Change From Baseline Freezing of Gait (FOG) After First 12 Weeks of Treatment, as Measured by the Giladi Freezing of Gait Questionnaire (FOG-Q). — 13.75; 14.57…

Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468

Primary: Change in Functional Connectivity to the Supplementary Motor Area. — -.176; .190 z-score

Primary: Number of Freezing of Gait (FoG) Episodes — 3.75; 5.17; 4.0; 3.63 number of freezes

Primary: Recruitment of Sample: Number of Participants Recruited — 12 Participants

Primary: Recruitment of Sample: Number of Participants Recruited — 12; 12 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events — 3; 1; 1; 1 Participants

Primary: Changes of the New Freezing of Gait Questionnaire (NFOGQ) Score — -1.60; -2.13 score on a scale

Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Related to aDBS — 0; 0; 0 Number of Treatment Emergent AEs

Primary: Change of Freezing of Gait Questionnaire (FOG-Q) — 12.0; 13.9 score

Primary: To Validate the Haptic Module and Insole Device System and Evaluate Its Efficacy With an In-community Clinical Trial. — 4.40; 5.69 seconds

Primary: Mean Change From Baseline (Visit 1 Until Visit 2) to Endpoint (After Visit 2 Until Visit 3) in the Freezing of Gait Questionnaire Score. — 1.25 change in FOGQ score…

Primary: Change in Gait Capacity as Assessed b 6-Minute Walk Test — 235.7; 150.0 Feet

Primary: The Primary Outcome Measure Was Change in a Gait Stride Length Between Groups at 12 and 27 Weeks. — 107.66; 112.29; 103.35 centimeters

Primary: Freezing of Gait — 2.6; 1.5 freezing of gait episodes

Primary: Functional Ambulation Profile (FAP) Score — 99.2; 86.8 FAP score on a scale

Primary: Change in Gait Speed- Sham_On — -0.0185 meters per second (m/s)

Primary: Sensory Organization Test - Composite Score — 7.7; 0.6 score on a scale

Primary: Reaction Time and Variability for Movement Task — 1013.858333; 994.94875; 979.2450877; 910.9120833 milliseconds

Primary: Gait Speed Before and After Real and Sham tDCS. — 8.7; 8.6; 9.7; 9.5 Seconds

Primary: Visual Sampling Parameter: Saccade Frequency During Gait — 0.48; 0.76; 0.67; 0.77 Saccade frequency (sacc/sec)

Primary: Berg Balance Scale — 43.93; 41.14; 43.25; 45.13 score on a scale — p=0.05

Primary: Walking Velocity at Baseline and 3 Months — 103.28; 104.53; 111.21; 109.57 cm/sec

Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety & Tolerability] — 1 Participants

Primary: Longitudinal Change of Brain Network Activity — 0.41; 0.61; 2.21; 3.61 Z-score in PDRP — p=0.84

Primary: Frequency of Aspiration Events on Videofluoroscopic Swallow Study at Visit 1 — 0.6; 2.9; 1.2 score on a scale — p=<0.05

Primary: Change in Velocity — 0.03; 0.05 m/s

Primary: Physical Performance: The Short Physical Performance Battery (SPPB) — 8.78; 9.60; 8.89; 10.72 units on a scale

Primary: Walking Activity — -207.59; -135.24 change in average daily steps — p=.89

Primary: Gait Speed (m/s) — 1.14; 1.21; 1.22; 1.20 m/s